Ng J, Cai L, Girard L, Prall OWJ, Rajan N, Khoo C, Batrouney A, Byrne DJ, Boyd DK, Kersbergen AJ, Christie M, Minna JD, Burr ML, Sutherland KD. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clinical Cancer Research. 2024;30(9):10.1158/1078-0432.ccr-23-2360
Chen T, Lieschke E, Scott L, Boyd D, Sutherland K, Strasser A, Kelly G. Abstract LT06: Understanding the Role of Mutant TP53 in Lung Cancer Using Novel Genetically Engineered Mouse Models. Cancer Research. 2024;84(8_Supplement):10.1158/1538-7445.fcs2023-lt06
Ng J, Pan E, Johnston A, Ribera NT, Kersbergen A, Hess JB, Best SA, Tsui E, Steinfort D, Sutherland KD. A Multiplexed Approach to Assess Small Cell Lung Cancer Subtype Heterogeneity in Primary and Patient-Derived Tumor Samples. Methods in Molecular Biology. 2024;2806:10.1007/978-1-0716-3858-3_10
McDonald JA, Boyd D, Diepstraten S, Scott L, Tai L, Kueh A, Burr M, Best SA, Herold MJ, Sutherland KD. Abstract A043: Identifying critical vulnerabilities that sensitise Lkb1 -mutant lung adenocarcinoma to T cell mediated killing. Cancer Immunology Research. 2023;11(12_Supplement):10.1158/2326-6074.tumimm23-a043
Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends in Cancer. 2023;9(11):10.1016/j.trecan.2023.07.010
Weeden CE, Gayevskiy V, Marceaux C, Batey D, Tan T, Yokote K, Ribera NT, Clatch A, Christo S, Teh CE, Mitchell AJ, Trussart M, Rankin L, Obers A, McDonald JA, Sutherland KD, Sharma VJ, Starkey G, D’Costa R, Antippa P, Leong T, Steinfort D, Irving L, Swanton C, Gordon CL, Mackay LK, Speed TP, Gray DHD, Asselin-Labat M-L. Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. Cancer Cell. 2023;41(5):10.1016/j.ccell.2023.03.019
Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death & Differentiation. 2023;30(4):10.1038/s41418-023-01122-3
Wang Z, Hu H, Heitink L, Rogers K, You Y, Tan T, Suen CLW, Garnham A, Chen H, Lieschke E, Diepstraten ST, Chang C, Chen T, Moujalled D, Sutherland K, Lessene G, Sieber OM, Visvader J, Kelly GL, Strasser A. Correction to: The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells. Cell Death & Differentiation. 2023;30(4):10.1038/s41418-023-01137-w
Chen H, Nguyen NH, Magtoto CM, Cobbold SA, Bidgood GM, Guzman LGM, Richardson LW, Corbin J, Au AE, Lechtenberg BC, Feltham R, Sutherland KD, Grohmann C, Nicholson SE, Sleebs BE. Design and characterization of a heterobifunctional degrader of KEAP1. Redox Biology. 2023;59:10.1016/j.redox.2022.102552
Sparbier CE, Gillespie A, Gomez J, Kumari N, Motazedian A, Chan KL, Bell CC, Gilan O, Chan Y-C, Popp S, Gough DJ, Eckersley-Maslin MA, Dawson S-J, Lehner PJ, Sutherland KD, Ernst P, McGeehan GM, Lam EYN, Burr ML, Dawson MA. Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes. Nature Cell Biology. 2023;25(2):10.1038/s41556-022-01056-x